OOIR: Observatory of International Research

Papers

(The TQCC of Annals of Hepatology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
P- 16 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: A MULTIDISCIPLINARY APPROACH IN A COSTA RICAN COHORT	422
O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES	121
P- 43 HCV TESTING AND TREATMENT IN FOUR BRAZILIANS’ CORRECTIONAL SETTINGS	79
P-8 TRENDS IN ALCOHOL-ASSOCIATED CIRRHOSIS IN CHILE: A POPULATION STUDY BETWEEN 2001 TO 2020.	63
O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA	60
P-46 IMMUNOSUPPRESSION IN POST LIVER TRANSPLANTATION: REVIEW OF THE EXPERIENCE IN A CHILEAN UNIVERSITY HOSPITAL	53
Genome-wide DNA methylation and transcriptomic analysis of liver tissues subjected to early ischemia/reperfusion injury upon human liver transplantation	47
P-110 CHANGES IN THE CLINICAL PRESENTATION OF PRIMARY BILIARY CHOLANGITIS (PBC) OVER THE YEARS IN A UNIVERSITY CENTER IN ARGENTINA	46
Association of IFNL3 gene rs4803217 with spontaneous clearance of Hepatitis C virus in patients from West Mexico	40
P- 91 CHANGES IN EARLY VISUAL PERCEPTION IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY	33
A thorny matter: Spur cell anemia	32
Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH	30
Skeletal muscle as a source of IGFBP-2 in a murine model of metabolic dysfunction associated with steatotic liver disease.	30
Development of a biodegradable prosthesis through tissue engineering, for the organ-replacement or substitution of the extrahepatic bile duct	29
Correspondence: “A multisociety Delphi consensus statement on new fatty liver disease nomenclature”	29
Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma	28
A practical approach to the endoscopic management of biliary strictures after liver transplantation	28
Characterization and determination of prevalence in autoimmune liver diseases in a tertiary center.	27
Neutrophil/lymphocyte index as a prognostic predictor in patients with primary biliary cholangitis	27
Acute Liver Failure due to Hepatitis A Virus: A Report of Two Cases	27
Kasabach-Merritt syndrome in an adult treated by embolization prior to liver transplantation: a case report.	26
Reply to: “correspondence about “Efficacy and safety of basiliximab”	26
“THE EFFECT OF GROWTH DIFFERENTIATION FACTOR 11 (GDF11) ON THE RESPONSE OF TUMOR-ASSOCIATED MACROPHAGES IN HEPATOCELLULAR CARCINOMA DERIVED CELLS”	25
Examining genetic associations with hepatic steatosis in Mexican-origin adults	24
Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms	24

Etiology and find in portal vein thrombosis at the Hospital de Especialidades del Centro Médico Nacional La Raza	23
Levels of IGFBP-1, 3 and 7 in human serum induced by alcohol consumption, NAFLD and dual insult	22
Short-term efficacy and safety of l-ornithine l-aspartate therapy in patients with cirrhosis and minimal hepatic encephalopathy: a real-life cohort study	22
CRITICAL MEDIATORS OF INFLAMMATION-DRIVEN HEPATOCARCINOGENESIS INDUCED BY METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	21
Lipocalin-2 silencing alleviates sepsis-induced liver injury through inhibition of ferroptosis	21
INFLUENCE OF GLYCEMIC CONTROL ON THE SEVERITY OF HEPATIC STEATOLOGY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS	21
Targeting cellular senescence as a therapeutic approach in non-alcoholic steatohepatitis	21
PLANT-DERIVED MONOTERPENE SYNERGIZES WITH SORAFENIB TO SUPPRESS DRUG-TRIGGERED HEPATOCELLULAR CARCINOMA IN ANIMALS	20
THE RELATIONSHIP BETWEEN QUALITY OF LIFE IN ADULT SUBJECTS WITH COMPENSATED LIVER CIRRHOSIS AND BACTERIAL OVERGROWTH	20
IMPROVEMENT OF CARDIOVASCULAR RISK ASSESSMENT ON A COHORT OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)	20
AUTOIMMUNE HEPATITIS IN LATIN AMERICA: INSIGHTS FROM THE ALLATIN COHORT	20
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics	19
Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database	19
Energy metabolism: An emerging therapeutic frontier in liver fibrosis	19
Tumor-associated macrophages contribute to cholangiocarcinoma progression and chemoresistance through activation of ID1	18
Comment on “burden of disease and risk factors for primary liver cancer by etiology in the United States, 1990–2021: Results from the global burden of disease study, 2021”	18
P-65 NEOPORTA WITH OR WITHOUT TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AS A VIABLE TREATMENT OF CHRONIC PORTAL VEIN THROMBOSIS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS	18
DILI and Dress syndrome secondary to treatment with DoTbal, in a patient with tuberculosis at the rural hospital from Papantla – IMSS Bienestar	18
Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay	18
P-106 DIAGNOSTIC ACCURACY OF SHEAR-WAVE ELASTOGRAPHY IN METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE, A SINGLE CENTER REPORT	18
Epidemiology and natural history of chronic Hepatitis B in the Canadian province of Alberta from 2012 to 2021: A population-based study	18
Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045	18
P-40 ASSOCIATION BETWEEN LIVER STIFFNESS MEASUREMENTS USING MR ELASTOGRAPHY AND PORTOSYSTEMIC SHUNTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE	18
P-19 ASSOCIATION OF TM6SF2 GENE POLYMORPHISMS WITH CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A HISPANIC ADULT POPULATION	18
Liver Injury Induced by Peumus boldus with Fatal Outcome. Case Report	17
Ceftriaxone versus cefotaxime in the treatment of spontaneous bacterial peritonitis	17
Prevalence of fibrosis and steatosis determined by transient elastography and controlled attenuation parameter (Fibroscan®) in diabetic patients	17
TSH and its Correlation in the Development of Fibrosis in Patients with Hypothyroidism in a Tertiary Care Hospital	17
The Hepatic Effect of Sub-chronic Chronic Cadmium Exposure.	16
The dual role of HCV protein expression in communication between host cells presents potential applications in the treatment of liver fibrosis	16
HEPATOCELLULAR CARCINOMA IN VERACRUZ: A SURVEILLANCE COMPARISON BETWEEN TREATMENTS	16
OP-3 HCV MICROELIMINATION PROGRAM IN HEMODIALYSIS PATIENTS: SUCCESS OF A MULTI-STAKEHOLDER PARTNERSHIP BASED ON A NATIONAL ERADICATION STRATEGY	16
Autoimmune hepatitis with superimposition of primary sclerosing cholangitis on non-specific chronic ulcerative colitis	15
Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project	15
An exploratory analysis of patient factors influencing acceptance of extended criteria liver grafts	15
PORTA VEIN THROMBOSIS (PVT) IN CIRRHOTIC PATIENTS PRE AND DURING THE PANDEMIC BY SARS-COV2	15
Trajectories of patients relisted for liver transplantation	14
IGFBP2: a possible molecular link between liver, heart, and bloodstream during metabolic dysfunction-associated steatotic liver disease	14
Gradual dosing of ursodeoxycholic acid in mothers with intrahepatic cholestasis of pregnancy may improve composite neonatal outcome	14
PROFILE OF PRO AND ANTI-INFLAMMATORY CYTOKINES IN PATIENTS WITH CHRONIC LIVER DISEASE IN THE COMPENSATION, INFLAMMATION AND IMMUNOSUPPRESSION PHASES	14
Moringa oleifera decreases biomarkers of oxidative stress in a murine NASH model	14
P-15 MMP-2 AND MMP-9 LEVELS IN ALCOHOLIC LIVER DISEASE, NON-ALCOHOLIC FATTY LIVER DISEASE AND CHRONIC HEPATITIS C	14
OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA	13
P-13 PREVALENCE, CHARACTERIZATION, AND SURVIVAL OF ACUTE ON CHRONIC LIVER FAILURE IN A LATIN AMERICAN COHORT: A MULTICENTER STUDY	13
Detection of Hepatitis C and risk factors in the general population of the Centro Médico Nacional La Raza	13
P-2 DE NOVO LIPOGENESIS MARKERS ARE INVOLVED IN METABOLIC ASSOCIATED FATTY LIVER DISEASE PROGRESSION IN BTBR OB/OB MICE	13
Treatment with nucleoside and nucleotide analogues in patients with chronic hepatitis B virus infection	13
P-123 HEPATOCELLULAR CARCINOMA SURVIVAL: EXPERIENCE OF THE MULTIDISCIPLINARY COMMITTEE AT HOSPITAL ESPECIALIDADES EUGENIO ESPEJO IN QUITO – ECUADOR	13
DRUG-INDUCED DUCTOPENIA IN THE SPANISH AND LATINDILI REGISTRIES	12
CLINICAL RESULTS IN PATIENTS WITH GASTROESOPHAGEAL VARICEAL BLEEDING IN THE ICU: ANALYSIS OF 85 CASES IN A TERTIARY CARE CENTRE	12

Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis	12
PROGNOSTIC VALUE OF AST/ALT AND GGT/ALP RATIOS IN PATIENTS WITH CHOLANGIOCARCINOMA	12
LIPOUNITS: A NOVEL UNIT OF MEASUREMENT TO COMMUNICATE THE IMPACT OF DAILY HABITS ON LIVER FAT IN PATIENTS WITH MASLD	12
INCIDENCE AND PREDICTORS OF POST-TRANSPLANT MALIGNANCY IN LIVER TRANSPLANT RECIPIENTS: A SINGLE-CENTRE COHORT STUDY	12
P- 26 EFFECT OF PROTEIN X OF THE HEPATITIS B VIRUS AND HEXACHLOROBENZENE ON LIVER CELL GROWTH DYSREGULATION	12
HEPATITIS C SCREENING AND GENDER DISPARITIES IN POSITIVITY RATES IN ARGENTINA	12
NURSING CARE STRATEGIES FOR INDIVIDUALS WITH VIRAL HEPATITIS IN THE CONTEXT OF PRIMARY HEALTH CARE	12
IMPACT OF REFRACTORY ASCITES ON THE SURVIVAL OF PATIENTS WITH CIRRHOSIS	11
Evaluation of the MELNa AGIB Scale to Predict Mortality in Patients with Cirrhosis and Variceal Hemorrhage.	11
Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017–2020 and genome-wide association study analysis	11
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT	11
DETERMINATION OF LEUKOCYTE PROFILE IN CHRONIC ALCOHOL CONSUMPTION	11
P- 18 ANASTROZOLE MAY NOT BE ASSOCIATED FATTY LIVER DISEASE AND HEPATIC FIBROSIS IN WOMEN WITH BREAST CANCER	11
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease	11
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis	11
P-4 RISK OF HCC IN SOUTH AMERICANS ASSOCIATED WITH TLL1 VARIANT SINGLE NUCLEOTIDE POLYMORPHISM	11
Data mining reveals novel gene drivers of lenvatinib resistance in hepatocellular carcinoma	11
Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico	10
Jejunal lymphoma of large cell high grade B monomorphic in a patient with hepatic transplant	10
Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma	10
Role of tamsulosin in recovery from thioacetamide-induced subchronic liver damage in a Wistar rat model	10
Clues to decipher the origin of severe acute hepatitis in children: a new enigma during the COVID-19 pandemic	10
Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023	10
Evaluation of the early response to empirical treatment and its association with cultures in patients with spontaneous bacterial peritonitis (SBP)	10
Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease	10
P- 107 EPIDEMIOLOGY, CLINICAL AND TISSUE CHARACTERISTICS OF A LARGE COHORT OF NAFLD/NASH FROM SOUTH AMERICA	10
Efficacy and safety of intravenous L-ornithine L-aspartate in patients with grade III and IV hepatic encephalopathy	10
NON-INVASIVE ASSESSMENT OF STEATOHEPATITIS AND LIVER FIBROSIS IN THE POPULATION AT RISK FOR METABOLIC STEATOTIC LIVER DISEASE	9
Serum Immunoglobulin M levels and neutrophil/lymphocyte index as predictors of treatment response in patients with primary biliary cholangitis	9
P-41 MICRORNAs FROM EVs AS POTENTIAL LIVER FIBROSIS NON-INVASIVE BIOMARKERS IN CHRONIC HEPATITIS C	9
Hepatic histologic findings in a murine model of diet induced-steatotic liver disease and acute alcohol intake	9
PROGNOSTIC ABILITY OF DIFFERENT SCORING SYSTEMS TO PREDICT VERY EARLY MORTALITY IN PATIENTS WITH CIRRHOSIS AND ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)	9
FUELING THE FIRE: INFECTIONS TRIGGER AND MALNUTRITION DRIVES SEVERE ACLF IN CIRRHOSIS	9
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease	8
MAFLD vs. MASLD: Consensus is unlike evidence!	8
O-13 SUB-OPTIMAL GLOBAL PUBLIC HEALTH POLICIES AND STRATEGIES TO TACKLE HEPATOCELLULAR CARCINOMA	8
Editorial board	8
IL-18 discriminates highly frequent hepatitis E virus positive from negative blood donors in Mexico	8
Involvement of the hedgehog signaling pathway in liver diseases	8
Prevalence of liver cirrhosis based on the metabolic health and weight criteria: Report from the Korea National Health and Nutrition Examination Survey (KNHANES) data analysis	8
P-87 TRANSCULTURAL ADAPTATION OF THE MEDITERRANEAN DIET TO THE DIETARY HABITS OF EACH GEOGRAPHICAL REGION OF ARGENTINA FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MA	8
EDITORIAL BOARD	8
MRI Imaging and Machine Learning Based Radiomics for Detection of Mixed HCC and CCA Tumors	8
Stroop test, Quickstroop, and the 1-min animal naming test for minimal hepatic encephalopathy diagnosis: A multicenter study in Mexico	8
P-44 LONG-TERM SURVIVAL IN PATIENTS WITH LIVER TRANSPLANTATION	8
OP-1 FEATURES OF IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN LATIN AMERICA: LONG-TERM EXPERIENCE OF THE LATINDILI NETWORK	8
Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany	8
O-11 THE PUBLIC HEALTH POLICIES REDUCE THE LONG-TERM BURDEN OF ALCOHOL-ASSOCIATED LIVER DISEASE WORLDWIDE: DEVELOPMENT OF A PREPAREDNESS INDEX	7
HEPATOCELLULAR CARCINOMA: CLINICAL AND EPIDEMIOLOGICAL FEATURES IN VERACRUZ	7
Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease	7
Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH	7
Different measures of sodium intake and the risk of metabolic dysfunction-associated steatotic liver disease: Evidence from the UK Biobank	7
Liver cirrhosis is a risk factor for poor prognosis of acute cholangitis caused by choledocholithiasis	7
CLINICAL CHARACTERIZATION OF HCC IN A SILENT REGION: REAL-WORLD DATA FROM A PROSPECTIVE COHORT IN CENTRAL AMERICA	7
Alarming increase of acute liver failure during Sudan’s conflict: a call for urgent global hepatology response	7
Regulation of TGF-β1, 2, and 3 and IL-10 at systemic level in chronic liver disease	7
TCD assessment in fulminant hepatic failure: Improvements in cerebral autoregulation after liver transplantation	7
P-14 SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: PREVALENCE AND ANTIBIOTIC RESISTANCE PATTERNS	7
EDITORIAL BOARD	7
Endohepatology: current status and perspectives	7
LONG-TERM ALBUMIN THERAPY MAY IMPROVE SURVIVAL IN CIRRHOSIS WITH ASCITES: A SYSTEMATIC REVIEW AND META-ANALYSIS	7
WHAT IS THE PROGNOSTIC VALUE OF A BLOOD TEST COUNT IN PATIENTS WITH ALCOHOLIC HEPATITIS?	7
Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis	7
EDITORIAL BOARD	7
Differential effect of the allele G ADRB2 (rs1042714) and allele C ADRB3 (rs4994) and its association with metabolic-associated steatotic liver disease (MASLD) risk factors in Mexican population.	7
Autoimmune hemolytic anemia as a paraneoplastic syndrome in hepatocarcinoma, case report	7
EDITORIAL BOARD	7
Efficacy of blood plasma spectroscopy for early liver cancer diagnostics in obese patients	7
NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN THE POPULATION WITH TYPE 2 DIABETES AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	7
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination	7
Management of hepatocellular carcinoma recurrence after liver transplantation	6
Editorial board	6
Validation of the Hepamet fibrosis score in a multi-ethnic Asian population	6
Metabolic dysfunction: The silenced connection with fatty liver disease	6
Comment on “Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study”	6
OP-5 ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) CRITERIA IN ALCOHOL-ASSOCIATED HEPATITIS: IMPLICATIONS FOR LIVER TRANSPLANTATION	6
O-14 NON-ALCOHOLIC FATTY LIVER DISEASE IS INFLUENCED BY THE INTERACTION OF HELICOBACTER PYLORI INFECTION AND G-ALLELE OF PNPLA3	6
Most Common Complications in Patients Post Liver Transplantation at a Hospital in Mexico.	6
Clinical spectrum and long-term outcomes of non-cirrhotic portal venous system thrombosis in Hispanic population	6
Radiofrequency ablation and percutaneous ethanol injection versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis	6

Demographic and clinical characteristics of MASLD and Met-ALD patients: Insights from NHANES 2017–2020	6
Prevalence of hepatic encephalopathy in non-cirrhotic portal hypertension: A systematic review and meta-analysis	6
From NAFLD to MASLD: Promise and pitfalls of a new definition	6
P- 42 METABOLIC ASSOCIATED FATTY LIVER DISEASE AND BODY COMPOSITION MEASUREMENT	6
Risk factors for sarcopenia in cirrhotic patients under evaluation for liver transplantation.	6
Efficacy of prophylactic antibiotics in the adjuvant treatment of alcohol-related liver disease (ALD): A systematic review and meta-analysisProphylactic antibiotics in ALD	6
P-121 SEPTIC SHOCK IN LIVER CIRRHOSIS: A COHORT STUDY OF A UNIVERSITY HOSPITAL IN CHILE	6
Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina	6
Comment on “Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease”	6
P-75 INFLUENCE OF THE ARTERIAL HEPATIC FLOW IN ELASTOGRAPHY (2D SHEARWAVE) LIVER VALUES	6
Predictive role of microvesicles in cirrhotic patients: A promised land or a land of confusion? A narrative review	6
Daytime napping and risk of liver cancer: A large population-based prospective cohort study	5
Hepatitis C virus NS5A and core proteins regulate epithelial-mesenchymal transition biomarkers in hepatoma cells	5
The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophilia	5
P-7 EPIDEMIOLOGY OF AUTOIMMUNE HEPATITIS IN LATIN AMERICA: PRELIMINARY RESULTS FROM ALLATIN COHORT	5
ELIMINATION OF HEPATITIS C AMONG HEMODIALYSIS PATIENTS IN ALAGOAS, BRAZIL	5
Outcomes of liver transplantation in patients 70 years or older: a systematic review and meta-analysis	5
Hepatocellular carcinoma and upper gastrointestinal bleeding	5
Circular RNA hsa_circ_0098181 inhibits metastasis in hepatocellular carcinoma by activating the Hippo signaling pathway via interaction with eEF2	5
Sarcopenia in patients with liver cirrhosis according to hepatic functional reserve	5
Diethylnitrosamine and 2-acetylaminofluorene chronic administration leads to biochemical and histologic changes related to hepatocellular carcinoma in Wistar rats	5
Interpretive bias on research evidence: Striving to meet the trustworthiness criteria	5
Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease	5
One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection	5
P-77 TRIPLE THERAPY FOR DIFFICULT-TO-TREAT PRIMARY BILIARY CHOLANGITIS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS	5
Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients	5
Short-term response of p300 evoked potential in patients with minimal hepatic encephalopathy treated with l-ornithine, l-aspartate	5
P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS	5
P- 54 HEPATITIS C MICROELIMINATION IN FORMER DRUG USERS	5
Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease	5
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.)	5
ARTIFICIAL INTELLIGENCE IN PREDICTING THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH METABOLICALLY ASSOCIATED STEATOTIC LIVER DISEASE: DEVELOPMENT AND VALIDATION OF A PREDICTIVE MODEL IN 306 PA	5
OP-13 CHOLANGIOCARCINOMA IN LATIN AMERICA: A MULTICENTER OBSERVATIONAL STUDY ALERTS ON ETHNICAL DISPARITIES IN TUMOR PRESENTATION AND OUTCOME	5
IMPORTANCE OF P450 POLYMORPHISM IN THE DEVELOPMENT OF DILI/HILI: HISTOLOGICAL AND BIOCHEMICAL FINDINGS	5
CORRELATION BETWEEN SARCOPENIA AND HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS	5
SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for	5
Good post-transplant outcomes using liver donors after circulatory death when applying strict selection criteria: a propensity-score matched-cohort study	5
Evaluation of the hepatoprotective effect of Flourensia cernua against the damage induced ischemia-reperfusion in Wistar rats.	5
Hepatoprotective effects of N-acetylcysteine prevents hepatocellular carcinoma development induced experimentally.	4
Ethanol with thioacetamide murine model of alcoholic liver disease identifies hepatic pathways as targets for the human disease	4
Portal cholangiopathy secondary to cavernomatous transformation of the portal vein. Case report	4
Colorimetric test for early diagnosis of spontaneous bacterial peritonitis.	4
O-2 CHARACTERIZATION OF SERUM LEVELS OF BILE ACIDS, EXTRACELLULAR VESICLES AND ITS CARGO IN ALCOHOL-ASSOCIATED LIVER DISEASE	4
O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY	4
P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C	4
O-37 AMOXICILLIN-CLAVULANATE INDUCED LIVER INJURY: TEN YEARS EXPERIENCE FROM LATINDILI REGISTRY.	4
Evaluation of the ALBI, MELD, MELD-Na, MELD 3.0 score in patients with hepatocellular carcinoma treated with Yttrium-90 (90y)	4
EncephalApp Stroop Test validation for the screening of minimal hepatic encephalopathy in Brazil	4
Influence of socioeconomic factors on liver transplant survival outcomes in patients with autoimmune liver disease in the United States	4
P- 39 N-ACETYL CYSTEINE ATTENUATES ALTERATIONS GENERATED IN EXPERIMENTAL LIVER STEATOSIS INDUCED BY CHRONIC ALCOHOL CONSUMPTION PLUS A HYPERCALORIC DIET	4
EDITORIAL BOARD	4
CLIF-C-ACLF scale to predict mortality in pediatric patients with acute-on-chronic liver failure	4
LIVER FIBROSIS IN INDIVIDUALS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN LATIN AMERICA: INTERIM RESULTS FROM THE STELLA STUDY	4
Cavin1 activates the Wnt/β-catenin pathway to influence the proliferation and migration of hepatocellular carcinoma	4
P-121 CORRELATION BETWEEN HEPATOPULMONARY SYNDROME AND OXYGEN SATURATION PULSE OXIMETRY IN CIRRHOTIC PATIENTS	4
A multinational survey of physician knowledge about management of chronic hepatitis C	4
MCM3 promotes hepatocellular carcinoma progression via Epithelial-mesenchymal Transition through AKT/Twist signaling pathway	4
Prevalence and evaluation of sleep disturbances in Mexican patients with hepatic cirrhosis through the application of the Pittsburgh sleep questionnaire	4
O-11 ENHANCEMENT OF F4/80+CD11B-CD206+ KUPFFER CELLS IN LIVER TISSUE: EFFECT OF MARESIN-1 AS HEPATOPROTECTIVE AGENT	4
P- 73 ULTRASOUND VISUALIZATION OF THE LIVER	4
Sarcopenia as a predictor of risk of minimal hepatic encephalopathy in patients with liver cirrhosis	4
Evaluation of the hypolipidemic effect of cinnamon essential oil in a model of acute damage induced by triton WR-1339	4
MORTALITY TRENDS AND RISK FACTORS IN ALCOHOL-ASSOCIATED HEPATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS	3
Integrated analyses and a novel nomogram for the prediction of significant fibrosis in patients	3
P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.	3
O- 5 HCC RISK SCORE PRE AND POST SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS TREATED FOR CHRONIC HEPATITIS C	3
CHOLANGIOCARCINOMA IN INDIVIDUALS WITH CHRONIC LIVER DISEASE IS DIAGNOSED EARLIER, LEADING TO BETTER PROGNOSIS	3
CLINICAL, BIOCHEMICAL, AND IMAGE CHARACTERISTICS IN PATIENTS WITH A DIAGNOSIS OF AMEBIC AND BACTERIAL LIVER ABSCESS.	3
Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value	3
FROM POLICY TO PRACTICE: HEPATITIS C CARE INDICATORS IN URUGUAY BEFORE AND AFTER THE INTRODUCTION OF PUBLIC HEALTH STRATEGIES	3
P-50 CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH ACUTE HEPATITIS B VIRUS IN A PUBLICAL HOSPITAL IN CHILE FROM 2015 TO 2022.	3
P-12 METHYL GROUP DONOR SUPPLEMENTATION IN A MetALD MODEL: REGULATION OF GUT MICROBIOTA AND METABOLIC PARAMETERS	3
P- 39 CLINICAL SIGNIFICANCE OF GRADE 1 HEPATIC ENCEPHALOPATHY IN PATIENTS HOSPITALIZED FOR COMPLICATIONS OF CIRRHOSIS	3
O-22 DIFFERENTIAL MUTATION PATTERN ASSOCIATED WITH HEPATITIS B E ANTIGEN SEROCONVERSION BETWEEN SUBGENOTYPE F1b CLUSTERS: POTENTIAL ROLE IN PATHOGENESIS	3
Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel	3
Correlation of Cardiovascular Risk Score with Alterations in Carotid Intima-Media Thickness in Patients with MASLD	3
Liver fibrosis: More than meets the eye	3
P-27 DESCRIPTIVE STUDY ON PATIENTS WITH HEPATOCARCINOMA IN A PUBLIC HOSPITAL 2018-2023	3
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019	3
Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts	3
O-20 EFFECTS OF ISOCALORIC AND NEGATIVE CALORIE BALANCE EXERCISE ON SERUM LEVELS OF INSULIN-LIKE GROWTH FACTOR TYPE 1 IN SUBJECTS WITH INITIAL AND ADVANCED FATTY LIVER	3
O-3 DEVELOPMENT OF LENTIVIRAL VECTORS FOR INHIBITION OF HEPATITIS B VIRUS VIA SMALL INTERFERING RNA	3
Knockdown of long non-coding RNA LINC01006 represses the development of hepatocellular carcinoma by modulating the miR-194-5p/CADM1 axis	3
P- 44 HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS IN A PARAGUAYAN LIVER REFERENCE CENTER: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS	3
FREQUENCY OF HEPATIC FUNCTION ALTERATION IN MEXICAN PATIENTS WITH COVID-19 AND ITS ASSOCIATION WITH THE SEVERITY OF ACUTE RESPIRATORY DISTRESS SYNDROME: PRELIMINARY RESULTS	3
ANALYSIS OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AND C-REACTIVE PROTEIN IN CIRRHOTIC PATIENTS WITH BACTERIAL, FUNGAL, AND VIRAL INFECTIONS: A CROSS-SECTIONAL STUDY	3
Impact of bilirubin molecular species on mortality in patients with acute on chronic liver failure (ACLF).	3
P-109 ALKALINE PHOSPHATASE AND CIRRHOSIS AT DIAGNOSIS ARE ASSOCIATED WITH DEEP RESPONSE TO URSODEOXYCHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS	3
Drug pricing for hepatitis B and C in Australia and Japan	3
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?	3
PRIMARY BILIARY CHOLANGITIS AT A TERTIARY CARE HOSPITAL	3
Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis	3
P-85 IMPACT OF TECHNICAL NOTE No 32/2021 ON THE RATE OF LIVER TRANSPLANTS FOR REFRACTORY ASCITIS IN A TERTIARY HOSPITAL	3
An Acknowledgement	3
O-1 ECONOMIC IMPACT OF LONG-TERM ALBUMIN INFUSIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND UNCOMPLICATED ASCITES FROM THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS PERSPECTIVES	3